Sleepwalking, REM Sleep Behaviour Disorder and Overlap Parasomnia in Patients with Parkinson's Disease by Di Fabio, N et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
Sleepwalking, REM Sleep Behaviour Disorder and Overlap Parasomnia in
Patients with Parkinson’s Disease
Di Fabio, N; Poryazova, R; Oberholzer, M; Baumann, C R; Bassetti, C L
Abstract: Background/Aims: In a questionnaire survey, we identified 36 (9%) of 417 Parkinson’s disease
(PD) patients with sleepwalking (SW); 72% of them also had a history of REM sleep behaviour disor-
der (RBD). We aimed to assess the clinical and polysomnographic characteristics of SW in PD and to
compare them to patients with PD with and without a history of RBD. Methods: We performed video-
polysomnography and detailed clinical examination in 30 PD patients from the above-mentioned survey:
10 patients with a history of SW, 10 patients with a history of RBD, and 10 patients with no history of
either SW or RBD. Results: PD patients with SW had higher depression, anxiety and Hoehn Yahr scores
and lower activities of daily living scores than patients without a history of RBD but did not differ from
patients with RBD. Patients with SW and RBD also had more often dyskinesia and hallucinations. By
polysomnography, RBD was observed in 8 patients with SW and in all patients with a history of RBD.
A total of 5 patients without a history of either SW or RBD had REM sleep without atonia without
behavioural peculiarities. Conclusion: SW in PD is associated with depression, higher disease severity
and functional disability. The simultaneous occurrence of SW and RBD (overlap parasomnia) in most
patients suggests a common underlying disturbance of motor control during sleep in PD, with variable
manifestations in different sleep stages.
DOI: 10.1159/000353378
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-85132
Veröffentlichte Version
Originally published at:
Di Fabio, N; Poryazova, R; Oberholzer, M; Baumann, C R; Bassetti, C L (2013). Sleepwalking, REM
Sleep Behaviour Disorder and Overlap Parasomnia in Patients with Parkinson’s Disease. European
Neurology, 70(5-6):297-303. DOI: 10.1159/000353378
E-Mail karger@karger.com
 Original Paper 
 Eur Neurol 2013;70:297–303 
 DOI: 10.1159/000353378 
 Sleepwalking, REM Sleep Behaviour 
Disorder and Overlap Parasomnia in 
Patients with Parkinson’s Disease 
 Nadia Di Fabio a    Rositsa Poryazova a    Michael Oberholzer b    
Christian R. Baumann a    Claudio L. Bassetti a, b  
 a  Department of Neurology, University Hospital Zurich,  Zurich , and  b  Department of Neurology, Inselspital,
 Bern , Switzerland 
 Conclusion: SW in PD is associated with depression, higher 
disease severity and functional disability. The simultaneous 
occurrence of SW and RBD (overlap parasomnia) in most pa-
tients suggests a common underlying disturbance of motor 
control during sleep in PD, with variable manifestations in 
different sleep stages.  © 2013 S. Karger AG, Basel 
 Introduction 
 Parasomnias are defined as undesirable motor phe-
nomena, behaviours, perceptions or emotions that occur 
predominately during the transition from wakefulness 
into sleep or arise during arousals from sleep. According 
to the International Classification of Sleep Disorders 
(ICSD-2), there are three main categories of parasomnias: 
NREM, REM, and other parasomnias  [1] . Sleepwalking 
(SW) is usually initiated during arousals from slow-wave 
sleep and presents with complex sleep-associated behav-
iour. Mental confusion during the episode and amnesia 
the next day are common. Injuries and violent behaviours 
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 Abstract 
 Background/Aims: In a questionnaire survey, we identified 
36 (9%) of 417 Parkinson’s disease (PD) patients with sleep-
walking (SW); 72% of them also had a history of REM sleep 
behaviour disorder (RBD). We aimed to assess the clinical 
and polysomnographic characteristics of SW in PD and to 
compare them to patients with PD with and without a his-
tory of RBD.  Methods: We performed video-polysomnogra-
phy and detailed clinical examination in 30 PD patients from 
the above-mentioned survey: 10 patients with a history of 
SW, 10 patients with a history of RBD, and 10 patients with 
no history of either SW or RBD.  Results: PD patients with SW 
had higher depression, anxiety and Hoehn & Yahr scores and 
lower activities of daily living scores than patients without a 
history of RBD but did not differ from patients with RBD. Pa-
tients with SW and RBD also had more often dyskinesia and 
hallucinations. By polysomnography, RBD was observed in 8 
patients with SW and in all patients with a history of RBD. A 
total of 5 patients without a history of either SW or RBD had 
REM sleep without atonia without behavioural peculiarities. 
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can also be observed  [1] . The prevalence of SW in chil-
dren is about 10% and in adults 2–3%, mostly persisting 
since childhood. Yet adult de novo SW is rare and may be 
observed in only 0.6%  [2] . Pathophysiologically, dissocia-
tion between motor and mental arousal is suggested. This 
hypothesis was supported by a study using single-photon 
emission computed tomography, showing deactivation 
of the frontoparietal associative cortices and activation of 
the cingulate cortex without deactivation in thalamus, 
usually observed in sleep  [3] . Polysomnographic findings 
may indicate an incomplete awakening, although a nor-
mal polysomnography (PSG) recording does not rule out 
SW.
 REM sleep behaviour disorder (RBD) is characterized 
by loss of the normal muscle atonia that accompanies 
REM sleep, thus allowing acting out dreams. It is usu-
ally associated with jerky, repetitive movements, though 
more complex behaviours have also been described  [4] .
 RBD has been studied in great detail in patients with 
Parkinson’s disease (PD), yet only a few studies examined 
NREM parasomnias in PD. An association between SW 
and PD has been reported in 3 patients in an abstract form 
 [5] . In a retrospective series, we found SW in 6 of 165 con-
secutive patients with PD  [6] . SW has been reported in 
PD patients with frequencies ranging from 2.1 to 5.3% 
 [7–9] , but detailed characteristics of the phenomenon 
were not studied. We recently performed a question-
naire-based survey specifically asking for SW and its 
characteristics in PD patients and found an even higher 
frequency (9%: 36 of 417 patients). 72% of these patients 
also had a history of RBD  [10] . Additionally, 42.6% of the 
417 patients had a history suggestive of RBD  [11] . The 
present study aimed at assessing the clinical and poly-
somnographic characteristics of SW in PD and compar-
ing them to patients with PD with and without a history 
of RBD.
 Patients and Methods 
 In an earlier study, which was performed in cooperation with 
the Parkinson’s Disease Patients’ Organization in Switzerland, we 
sent a questionnaire examining sleep habits and sleep-wake disor-
ders, especially sleep-related movement disorders such as SW and 
RBD in PD patients to the members of the organization together 
with its monthly magazine. A questionnaire on SW and the RBD 
screening questionnaire (RBDSQ) were included. RBDSQ is a self-
assessment tool consisting of 10 items, each requiring a ‘yes’ or ‘no’ 
answer  [12] . A score of 6 or higher on RBDSQ was found to predict 
RBD in patients with PD  [13] . All patients were asked if they had 
SW in their childhood and/or as adults. The patients who reported 
SW filled in a more detailed questionnaire on SW with 22 items on 
frequency of SW, occurrence during the night, recall, awakening 
during SW, most common and most complex activities during 
SW, relation of SW behaviour to dreams, injuries, violence, family 
history and precipitating factors  [10] . 417 questionnaires were re-
turned. Based on the history of SW and RBD, responders to the 
questionnaires were contacted and invited for a detailed clinical 
examination and overnight video-PSG. Of 36 PD patients, 10 (5 
men and 5 women with a mean age of 66 ± 11 years, SD) with a 
history of SW (in 4 of them since childhood and in 6 de novo) 
agreed to participate in the study. Of these 10 patients, 7 had 
RBDSQ scores  ≥ 6, suggestive of RBD which corresponds to the 
overall questionnaire data, where 72% of the patients reporting SW 
also had RBDSQ scores suggestive of RBD  [10] . Additionally, pa-
tients without a history of SW but with RBDSQ scores suggestive 
of RBD were invited to participate in the study. For this group we 
selected 10 patients (8 men and 2 women with a mean age of 65 ± 
7 years, SD) with high RBDSQ scores ( ≥ 10) to increase the possi-
bility of RBD. As a third group 10 patients (5 men and 5 women 
with mean age of 66 ± 10 years, SD) without a history of either SW 
or RBD were included. We selected patients with RBDSQ  ≤ 2 to 
reduce the possibility of RBD. The diagnosis of PD in all patients 
was confirmed and fulfilled international criteria  [14] .
 A detailed structured interview assessed sleep habits and sleep-
wake disorders, the presence of hallucinations, wearing off symp-
toms and dyskinesia. Disease severity was judged using the Unified 
Parkinson’s Disease Rating Scale, motor score (UPDRS part III), 
and the Activities of Daily Living (ADL) score according to Schwab 
and England. For cognitive assessment, we performed the Mini 
Mental State Examination (MMSE). Anxiety and depression were 
rated using the Beck Depression (BDI) and the Beck Anxiety In-
ventories (BAI). According to the user’s guidelines, scores of 0–9 
indicate minimal anxiety or depression, 10–16 mild, 17–29 moder-
ate, and 30–63 severe anxiety or depression  [15] . Sleepiness was 
assessed using the Epworth sleepiness scale (ESS). We also record-
ed the medical treatment of the patients and calculated the levodo-
pa-equivalent dose (LED) as previously reported  [16] .
 All 30 patients underwent standard nocturnal video-PSG con-
sisting of six-channel EEG (F3/A2, F4/A1, C3/A2, C4/A1, O1/A2, 
O2/A1), left and right electrooculography (EOG), submental, left 
and right anterior tibialis, flexor carpi radialis and adductor digiti 
minimi electromyography (EMG), electrocardiography (ECG), 
respiratory flow and effort, and pulse-oximetry. All recordings 
were done by Medcare Somnologica Studio. Sleep stages and sleep-
associated events were scored manually according to international 
criteria  [17] . Sleep onset was defined as the first epoch of either 
NREM 2 or REM sleep. REM sleep scoring of advanced PD pa-
tients was performed as previously suggested  [18] . For the poly-
somnographic diagnosis of REM sleep without atonia, we moni-
tored not only submental  [19] and lower limb EMG but also upper 
limb EMG activity as recently suggested  [20] .
 In addition, BAI and BDI questionnaires were sent to all other 
26 PD patients with a history of SW who were not able to partici-
pate in the clinical and polysomnographic study and to 26 patients 
with no history of either SW or RBD. 14 questionnaires from pa-
tients with a history of SW (11 men and 3 women, with a mean age 
of 72 ± 7.7 years, SD) and 12 questionnaires from patients without 
a history of either SW or RBD (9 men and 3 women with a mean 
age of 70.4 ± 7.3 years, SD) were returned.
 The study, performed at the Department of Neurology, Univer-
sity Hospital Zurich, was approved by the local ethics committee 
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(Kantonale Ethikkommission des Kantons Zürich) and all patients 
signed an informed consent prior to the study.
 Statistical analysis was performed using SPSS 18 software. 
ANOVA with post hoc tests with Bonferroni correction, t tests and 
χ 2 tests were used to analyse categorical and continuous variables, 
respectively. Significance level was set at p < 0.05.
 Results 
 The clinical characteristics of patients with and with-
out a history of SW or RBD are presented in  table 1 . Sig-
nificant differences between the groups were observed for 
BDI (p = 0.01), BAI (p = 0.03), Hoehn & Yahr (H&Y) 
(p = 0.022) and ADL scores (p = 0.012). Post hoc tests 
(with Bonferroni correction) revealed that the SW group 
had higher BDI (p = 0.009), BAI (p = 0.027) and H&Y 
scores (p = 0.023) and lower ADL scores (p = 0.017) than 
patients without a history of RBD but did not differ from 
patients with a history of RBD. Scores indicating moder-
ate or severe depression (scores of 17 or higher) were ob-
served in 5 patients with a history of SW and in 3 patients 
with a history of RBD; scores indicating moderate or se-
vere anxiety were observed in 4 patients with a history of 
SW and in 2 patients with a history of RBD, none of the 
patients with no history of RBD and SW had scores of 17 
or higher on BDI and BAI.
 There were also significant differences in the report-
ed frequency of dyskinesia (p = 0.015, reported in 6 pa-
tients with a history of RBD, 4 patients with a history of 
SW and in none of the patients with no history for SW 
or RBD) and hallucinations (p = 0.024, reported in 8 
patients with a history of SW, 6 patients with a history 
of RBD and in 2 patients with no history for SW or 
RBD).
 The analysis of the additional BDI and BAI question-
naires received from 14 patients with a history of SW and 
12 patients without a history of either SW or RBD, who 
did not participate in the clinical and electrophysiological 
part of the study, revealed even larger differences between 
patients with a history of SW and patients without a his-
tory of SW or RBD (p < 0.001 for both scores): BDI (16 ± 
9.3 in patients with a history of SW, 7 ± 4.7 in patients 
without a history of SW or RBD) and BAI (16.2 ± 9 in pa-
tients with a history of SW, 7.4 ± 4.5 in patients without 
a history of SW or RBD).
 Antiparkinsonian drugs included levodopa (n = 30), 
non-ergot (pramipexole, ropinirole and rotigotine) (n = 
24), ergot (pergolide) (n = 1) dopamine agonists (DA), 
catechol-O-methyl-transferase (COMT) inhibitors (n = 
12, in 7 patients with a history of RBD, in 3 patients with 
a history of SW and in 2 patients without a history of ei-
ther SW or RBD), amantadine (n = 6, in 2 patients from 
each group), monoamine oxidase A (MAO-A) inhibitors 
(n = 5, in 3 patients with a history of SW and in 2 with a 
history of RBD). Mean LED was 621.2 ± 582.8 mg in the 
SW group, 823.0 ± 217.2 mg in the RBD group, and 602.1 
± 425.2 mg in patients with no history of SW or RBD. 
Other relevant drugs included cholinesterase inhibitors 
(n = 2, in 1 patient with a history of SW and 1 patient with 
a history of RBD), neuroleptics (n = 3, 2 patients with 
a history of SW and 1 patient without a history of either 
SW or RBD), benzodiazepines (1 patient with RBD), 
Table 1. Demographic and clinical characteristics of PD patients with and without a history of SW or RBD (mean 
values with SD in parentheses)
SW (n = 10) RBD (n = 10) No SW or
RBD (n = 10)
p
Age, years 66 (11.6) 65.5 (7.3) 65.8 (9.7) n.s.
Male gender, % 50 80 50 n.s.
Disease duration, years 12.3 (9.1) 11.5 (5.3) 8.2 (6.9) n.s.
Therapy duration, years 11.1 (8.9) 9.8 (5.0) 7 (6.7) n.s.
LED, mg/day 671.2 (582.8) 823.0 (217.2) 602.1 (425.2) n.s.
UPDRS, part III 26.5 (14.6) 22.1 (9.8) 18.0 (8.0) n.s.
RBDSQ score 7.0 (2.7) 11.3 (0.9) 1.4 (0.5)
MMSE 27.1 (3.0) 28.7 (1.7) 27.7 (3.3) n.s.
BDI 14.6 (6.3) 11.4 (6.4) 6.2 (3.6) 0.01
BAI 15 (7.9) 10.4 (7.1) 6.6 (4.0) 0.03
H&Y score 3.1 (0.74) 2.5 (0.77) 2.2 (0.59) 0.022
Schwab & England score 64 (21.7) 81.0 (12.9) 84 (5.2) 0.012
ESS 14.4 (4.6) 9.90 (4.0) 10.8 (5.8) n.s.
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β-blockers (n = 4, 1 patient with a history of SW, 1 with a 
history of RBD and 2 without a history of either SW or 
RBD) and antidepressants (n = 6, 3 patients with a his-
tory of SW were treated with tricyclic antidepressants 
(TCA), 2 patients with a history of RBD, 1 with TCA and 
1 with a selective serotonin reuptake inhibitor (SSRI) and 
1 patient without a history of either SW or RBD was treat-
ed with a serotonin-noradrenaline reuptake inhibitor 
(SNRI). Two of the patients with a history of SW treated 
with TCA had SW since childhood, in 1 of them persis-
tent, she did not have RBD in PSG; in the other patient, 
SW ceased in adolescence and recurred with the begin-
ning of the PD symptoms, she also had RBD in PSG. The 
third patient reported SW and RBD since the beginning 
of the PD symptoms and did not associate it with the an-
tidepressive medication. The patient without a history of 
SW or RBD treated with SNRI presented with REM sleep 
without atonia in PSG.
 Quantitative PSG parameters did not differ between 
the groups ( table 2 ). As expected in all 10 patients with a 
history highly suggestive of RBD (RBDSQ  ≥ 10), the dis-
order was also confirmed polysomnographically. Of 10 
patients with a history of SW, 8 also exhibited RBD in 
their PSG; 6 of them had RBDSQ  ≥ 6, suggestive of RBD 
 [13] . In 1 patient with a history of SW and high RBDSQ 
score, RBD could not be confirmed in the PSG, yet in the 
original publication of the questionnaire it was stated that 
RBDSQ poorly discriminates RBD and SW. Two patients 
with a history of SW and a relatively low score of 4 on 
RBDSQ demonstrated RBD in their PSG. All patients 
with a history of RBD had not only pronounced twitching 
and body jerks, but also behavioural peculiarities such as 
hitting (n = 7), vocalisations (n = 6), laughing (n = 6), and 
gesturing (n = 3). In patients with SW and RBD, the latter 
presented not only with excessive twitching and body 
jerks but also with hitting (n = 4), head jerks (n = 3), vo-
calisations (n = 3), laughing (n = 3) or oral automatisms 
(n = 1). REM sleep without atonia without behavioural 
peculiarities was observed in 5 patients without a history 
of either SW or RBD. Sudden arousals from deep NREM 
sleep were observed in 2 patients with SW and 1 patient 
with RBD.
 Discussion 
 There were three main findings of the present study. 
First, patients with a history of SW and PD scored sig-
nificantly higher on depression and anxiety question-
naires as compared to PD patients with no history of ei-
ther SW or RBD. Second, PD patients with a history of 
SW had more advanced disease, higher impairment of 
ADL and reported more often hallucinations and dys-
kinesias. Third, polysomnographically, RBD was con-
firmed in 8 of 10 PD patients with a history of SW (in all 
6 patients with de novo SW) and in all 10 patients with a 
history of RBD. However, 5 patients with no history of 
SW and RBD had REM sleep without atonia. There were 
no significant differences in any quantitative sleep pa-
rameter.
Table 2.  Sleep measures in PD patients with and without a history of SW or RBD (mean ± SD values)
SW (n = 10) RBD (n = 10) No SW or
RBD (n = 10)
p
Latency to, min
Sleep onset 36.4 (65.8) 47.4 (89.9) 22.4 (12.7) n.s.
REM sleep 131.3 (81.8) 167.9 (103.4) 152.3 (75.0) n.s.
Total sleep time, min 336.8 (138.1) 332.0 (107.6) 338.1 (62.4) n.s.
Sleep duration, % total sleep time
Wake 24.1 (24.6) 27.5 (19.2) 27.4 (13.4) n.s.
NREM-1 16.0 (10.2) 10.8 (6.3) 14.0 (5.1) n.s.
NREM-2 35.2 (20.0) 32.1 (11.9) 32.2 (8.5) n.s.
Slow-wave sleep 12.8 (11.7) 12.3 (6.5) 15.9 (8.5) n.s.
REM 12.0 (7.3) 16.3 (8.3) 10.5 (4.7) n.s.
Sleep efficiency 75.9 (24.6) 72.5 (19.2) 72.6 (13.4) n.s.
Arousal index 10.5 (10.0) 7.5 (3.7) 13.5 (5.4) n.s.
Apnea/hypopnea index 8.1 (11.7) 10.3 (11.2) 14.9 (13.7) n.s.
Periodic limb movements in sleep 7.0 (12.6) 2.6 (5.0) 17.3 (32.8) n.s.
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 The prevalence of anxiety and depression in PD varies 
considerably according to different studies due to meth-
odological factors, yet a large body of evidence suggests a 
higher prevalence of depression in PD in comparison to 
the general elderly population and to other chronic dis-
eases (e.g. arthritis and diabetes)  [21] . A systematic re-
view of patients with PD found that major depression was 
present in 17%, minor depression in 22%, and dysthymia 
in 13%, whereas clinically relevant depressive symptoms 
were present in 35% of the PD patients  [22] . Additionally, 
a higher frequency of SW in depressed patients has been 
observed  [23] . NREM abnormalities have been shown in 
depressed subjects with a shift of the slow-wave δ activity 
to the initial part of the sleep period following psycho-
therapy. Subjects who experienced recurrence of depres-
sion showed less baseline slow-wave activity compared to 
those in remission after 1 year  [24] . It has been hypothe-
sized that NREM sleep abnormalities in depression might 
predispose to dysfunctional transitions between sleep 
and wakefulness, particularly in the early part of the sleep 
period  [25] . Thus there is some evidence for an associa-
tion between depression and SW. Furthermore, a number 
of drugs have been reported to occasionally induce SW: 
hypnotics, antipsychotics, antihistaminics, alcohol and 
especially antidepressants, including SSRI  [26–28] . Sero-
tonin (5-HT) neurons originating from the dorsal raphe 
nucleus project to the cholinergic laterodorsal and pe-
dunculopontine tegmental areas, inhibiting ‘REM-on’ 
neurons and therefore inhibiting REM sleep  [29] . SSRI, 
TCA (also through anticholinergic effects leading to re-
duced cholinergic atonia in REM sleep) and SNRI have 
all been found to increase the occurrence of both REM 
and NREM parasomnias  [23] . Patients on serotonergic 
antidepressants exhibited increased submental EMG 
during REM sleep, so an effect of 5-HT on motor systems 
at the spinal cord or brainstem level as a possible mecha-
nism has been suggested  [30] . Thus, 5-HT has been im-
plicated on the one hand in the regulation of sleep-wake-
fulness and motor control during sleep and on the other 
hand in the pathophysiology of RBD and SW  [31] as well 
as depression, including depression in PD  [32–34] . Politis 
et al.  [33] found that depressive symptoms in PD patients 
correlate with higher 5-HT transporter (5-HTT) binding 
in raphe nuclei and limbic structures, possibly reflecting 
lower extracellular 5-HT levels. Using the loudness de-
pendence of auditory-evoked potentials, an indicator of 
central serotonergic function, Beucke et al.  [32] suggested 
lower serotonergic activity in PD and assumed that this 
could be related to a high prevalence of depression in PD. 
The serotoninergic hypothesis of SW postulates that dis-
sociated activity of serotonergic neurons of the raphe nu-
clei of the brainstem and the serotonergic neurons which 
modulate the motor system may result in SW. These two 
neuronal systems are normally coordinated so that in-
creased arousal leads to increased motor activity, but 
when the two systems dissociate, SW can result  [26, 31] . 
It is therefore conceivable that serotonergic dysfunction 
in depression and PD influences sleep-wakefulness regu-
lation and motor control during both REM and NREM 
sleep and could possibly trigger RBD and SW. Indeed, our 
patients with PD and a history of SW, 8 of whom also had 
polysomnographically confirmed RBD, had significantly 
higher scores for depression and anxiety in comparison 
to patients without a history of either SW or RBD.
 In line with the findings of longer disease duration  [35] 
and higher disease severity  [36] in depressed patients with 
PD, our PD patients with a history of SW also suffered 
from more advanced disease (as measured by the H&Y 
stage score) and higher functional disability. The higher 
frequency of dyskinesias and hallucinations in these pa-
tients also suggest a more advanced disease. The presence 
of levodopa-induced dyskinesias is correlated with an in-
creased incidence of depression  [37] . Hallucinations have 
been linked to cognitive impairment in PD  [38] . Further-
more, nighttime wandering behaviour has been reported 
in male PD patients with cognitive decline living in nurs-
ing homes  [39] . However, using MMSE, we did not find 
significant differences between PD patients with a history 
of SW, RBD and no history of either of the two. On the 
one hand, hallucination can simply arise from a more ad-
vanced disease  [38, 40] . On the other hand, similar neu-
rodegenerative changes in brainstem and limbic struc-
tures may underlie both visual hallucinations and SW in 
PD  [40] . Recently, increased 5-HT 2A receptor binding in 
the ventral visual pathway has been reported in PD pa-
tients with visual hallucinations  [41] . Thus, 5-HT can be 
implicated not only in the pathophysiology of SW and 
depression in PD, but also in hallucinations.
 Quantitative polysomnographic parameters did not 
differ between PD patients with a history of SW, PD with 
a history of RBD and PD without a history of either SW 
or RBD. It should, however, be stressed that diagnosis of 
SW was based on history. In PSG, episodes suggestive of 
SW (sudden arousals from NREM sleep) were observed 
in 2 patients with a history of SW. No ambulatory behav-
iour was observed during sleep, yet according to ICSD-2 
 [1] , polysomnographic confirmation does not belong to 
the diagnostic criteria of SW. As we have previously dis-
cussed, we cannot rule out that SW represents a severe 
manifestation of RBD and is therefore present in only a 
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small number of patients with RBD. According to the 
ICSD-2  [1] , RBD is defined by the following criteria: (a) 
presence of REM sleep without atonia: the EMG finding 
of excessive amounts of sustained or intermittent eleva-
tion of submental EMG tone or excessive phasic submen-
tal or (upper or lower) limb EMG twitching; (b) at least 
one of the following: (i) sleep-related injurious, poten-
tially injurious, or disruptive behaviours by history; (ii) 
abnormal REM sleep behaviours documented during 
polysomnographic monitoring; (c) absence of EEG epi-
leptiform activity during REM sleep unless RBD can be 
clearly distinguished from any concurrent REM sleep-re-
lated seizure disorder, and (d) the sleep disorder is not 
better explained by another sleep disorder, medical or 
neurological disorder, mental disorder medication use, or 
substance use disorder. Restoration of motor control in 
PD during REM sleep has been hypothesized  [42] which 
would facilitate ambulatory activity. Getting out of bed 
and walking as a representation of RBD has been report-
ed in a few series of patients with idiopathic and symp-
tomatic RBD  [43, 44] . One could argue if an item should 
be added to RBDSQ to include ambulatory behaviour as 
a part of RBD. However, SW has not been documented 
with PSG to arise from REM sleep. In a detailed analysis 
of 100 patients with PD and a history of RBD, SW was 
observed in only 1 patient in whom RBD could not be 
demonstrated with PSG  [42] . RBD could be polysomno-
graphically confirmed in 8/10 PD patients with SW (in all 
6 patients with SW de novo). This is rather in favour of 
our hypothesis of a common underlying disturbance of 
motor control during sleep in PD, with variable manifes-
tations according to different sleep stages  [10] .
 However, REM sleep without atonia could be poly-
somnographically confirmed in 5 patients with no his-
tory of SW and RBD. These patients presented with 
twitching and occasional body jerks (in 5 out of 5), while 
all patients with a history for RBD and RBD and SW also 
showed behavioural peculiarities. This suggests a milder 
or beginning form of RBD and probably lesser or no 
nighttime impairment in patients with no history of RBD.
 Limitations of the present study include the small sam-
ple size and the lack of a healthy control group. We also 
have to note that 6 patients were treated with antidepres-
sants which are reported to increase the frequency of 
REM and NREM parasomnias. Two of these patients had 
SW since childhood, so antidepressive therapy could not 
have caused their SW episodes, yet it could have precipi-
tated their occurrence. We could not exclude patients on 
antidepressants as we were limited in our choice of pa-
tients to the results of the previously performed question-
naire study  [10] and the consent of the patients to par-
ticipate in the clinical and electrophysiological part of the 
study. Additionally, MMSE is only a screening tool and 
provides only limited information about cognitive im-
pairment in PD. As we had only 2 patients with a history 
of SW and no polysomnographically confirmed RBD, we 
could not compare patients with SW only and patients 
with both SW and RBD. This issue should be addressed 
by further studies. Thus far, all patients in each group 
were characterized clinically and electrophysiologically 
in detail.
 Conclusion 
 SW in PD is associated with depression, higher disease 
severity and higher functional disability. The simultane-
ous occurrence of SW and RBD (overlap parasomnia) in 
most patients suggests a common underlying disturbance 
of motor control during sleep in PD, with variable mani-
festations according to different sleep stages. It can also 
be speculated that 5-HT dysfunction might be the link 
between ambulatory behaviour during sleep, depression 
and hallucinations in PD.
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